China's drug regulator approved a new indication for Jiangsu Hengrui Pharmaceutical's (SHA:600276, HKG:1276) hetrombopag ethanolamine tablets, according to a Saturday filing with the Shanghai bourse.
The product is indicated for patients with chronic primary immune thrombocytopenic purpura, an acquired autoimmune disorder that mistakenly destroys platelets.
Hengrui's new drug is also indicated for severe aplastic anemia patients who are not responsive to immunosuppressive therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments